The Sahajanand IPO is structured as a sale by existing shareholders, not a fresh fundraising exercise for the medical-device company. Sahajanand Medical Technologies Limited’s RHP, dated October 9 and listed on SEBI’s website on October 10, schedules public bidding for October 15–19, 2026.
Company funding and seller proceeds are different
The cover specifies up to 13,822,116 existing shares with a ₹1 face value and marks a fresh issue as not applicable. In an offer for sale, or OFS, investors buy shares sold by current shareholders. The company’s “Objects of the Offer” section says the sale proceeds go to selling shareholders after their respective offer expenses; the issuer does not receive them.
This distinction prevents an easy mistake: describing the whole IPO as cash available to build capacity, repay debt or finance working capital. The RHP includes an employee reservation of up to 250,000 shares; that reservation does not turn the transaction into a fresh issue.
IPO facts
| Item | Verified detail |
|---|---|
| Maximum offered shares | Up to 13,822,116 shares |
| Fresh issue | Not applicable; no fresh shares |
| Offer for sale | Up to 13,822,116 existing shares |
| Face value | ₹1 per share |
| Anchor bidding | October 14, 2026 (scheduled) |
| Public bidding | October 15–19, 2026 (scheduled) |
| UPI mandate deadline | October 19, 2026, 5 PM IST |
| Allotment | On or about October 21, 2026 |
| Trading commencement | On or about October 23, 2026 |
| Proposed exchanges | BSE and NSE; final trading approval not verified |
| Registrar | MUFG Intime India Private Limited |
| Price band / lot / minimum amount | Not independently verified; reviewed RHP leaves these blank |
| Cash offer size | Not verified; offer price blank in reviewed RHP |
A medical-device business has specific approval risks
The opening risk factor says the business faces extensive regulatory requirements across its markets. Product approval or clearance can take time, require significant resources and testing, and limit permitted uses. These are the issuer’s disclosed business risks—not evidence that a particular approval has been refused or that a new enforcement action has occurred.
For readers comparing offers, business-specific risks should sit alongside the funding structure. Neither a prospectus on SEBI’s website nor a proposed exchange listing represents a guarantee of investment returns.
Do not confuse a schedule with completion
The indicative timetable places allotment around October 21, refunds or unblocking and share credit around October 22, and trading around October 23. These are planned checkpoints, not confirmed events at the time of this report. The closing-day UPI mandate deadline in the RHP is 5 PM IST on October 19; application entry and successful mandate acceptance are different steps.
The reviewed RHP leaves the price band and minimum lot blank for a separate announcement. CapKet has not verified that official advertisement, so this report deliberately omits a cash issue-size calculation and minimum application amount. Missing verification is not a zero price or zero lot. See CapKet’s Ravita report for the different treatment of fresh-share proceeds.
Primary sources and observation time
Checked at 18:55 IST on October 12, 2026: SEBI’s dated filing entry and the full official RHP. The cover, printed risk page 20, objects page 131 and timetable page 490 support this report. No subscription, final allotment, current share-price reaction or grey-market premium was verified.